2-Phenylethyl methyl ether is an aromatic ether best known as the signature odor constituent of kewra (Pandanus odorifer) flower oil, where it often dominates the profile. The strongest public evidence supports its identity, odor role, and repeated occurrence in kewra chemotypes, while the direct bioactivity literature remains much smaller and mostly nonclinical. For AromaForge it is best framed as a high-impact floral ether with limited but real antimicrobial and antibiofilm preclinical literature, plus clearer flavor-reference than therapeutic evidence.
Chemical identity and composition
PubChem resolves this constituent to CID 19089 with formula C9H12O and the IUPAC name 2-methoxyethylbenzene. ChEBI classifies it as a member of benzenes, while JECFA lists methyl phenethyl ether as flavouring substance 1254 with CAS 3558-60-9 and full specification status. In the local archive, kewra flower oil is explicitly described as a 2-phenylethyl methyl ether-rich floral ether type and lists it at 79% in the referenced profile.
Aroma and practical use
- Use the recorded floral, warm, penetrating, green, rosy, rose-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2018 phytochemical survey of 180 Pandanus odorifer flower samples reported phenylethyl methyl ether as the major constituent, ranging from 58.03% to 81.86% of the essential oil.
This is the strongest located source for constituent-level occurrence and chemotype relevance in kewra materials.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2023 Microbial Pathogenesis study found a minimum inhibitory concentration of 50 mM against tested strains and reported reduced Staphylococcus aureus biofilm formation, exopolysaccharides, and virulence-associated gene expression after 2-phenylethyl methyl ether exposure.
This is the clearest constituent-specific activity paper located in this pass, but it remains nonclinical and microorganism-focused.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 Frontiers in Microbiology study identified 2-phenylethyl methyl ether as one of the volatile compounds that significantly inhibited mycelial growth and spore germination of Colletotrichum gloeosporioides.
This supports broader antimicrobial relevance, but only in a plant-pathogen model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedJECFA lists methyl phenethyl ether with full flavouring specification status, which gives this constituent stronger food-flavor reference framing than most niche floral ethers.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A RIFM fragrance ingredient safety assessment for methyl phenethyl ether was published in 2022, but this pass did not extract a constituent-specific dermal-limit summary from the full article.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No constituent-specific human clinical tolerability or efficacy study was verified in this pass, so wellness-facing copy should stay descriptive rather than therapeutic.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
biofilm_gene_downregulation_in_staphylococcus_aureus
A 2023 study reported reduced biofilm formation with relative downregulation of agrA, sarA, norA, and mepR in Staphylococcus aureus after treatment with 2-phenylethyl methyl ether.
This experimental finding does not establish benefit, dose or safety in people using this blend.
volatile_antifungal_action_against_colletotrichum
A 2020 Frontiers in Microbiology paper identified 2-phenylethyl methyl ether among volatile compounds that inhibited mycelial growth and spore germination of Colletotrichum gloeosporioides.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No constituent-specific human clinical study was verified for isolated 2-phenylethyl methyl ether in this pass.
- The accessible activity literature is narrow and focused on microbial or plant-pathogen models rather than human translation.
- A directly extracted dermal-sensitization or IFRA-style limit was not verified from a readable primary source in this pass.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.